Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine

Brain Research
Małgorzata FilipKjell Fuxe

Abstract

Recent data indicate that cocaine locomotor responses may be influenced by dopamine (DA) neurotransmission and adenosine neuromodulation involving the A2A receptor (A2AR). Male Wistar rats were injected with MSX-3 (1-25 mg/kg; an antagonist of A2AR), CGS 21680 (0.05-0.2 mg/kg; an agonist of A2AR), SCH 23390 (0.125-0.25 mg/kg; an antagonist of DA D1/5R), raclopride (0.1-0.8 mg/kg; an antagonist of DA D2/3R), nafadotride (0.2-0.4 mg/kg; an antagonist of DA D3R) or 7-OH-PIPAT (0.01-1 mg/kg; an agonist of DA D3R) to verify the hypothesis that adenosine A2AR and DA receptors and their antagonistic interactions may control locomotor and sensitizing effects of cocaine. In well-habituated animals, MSX-3 (5 mg/kg) increased, while raclopride (0.4-0.8 mg/kg) decreased basal locomotor activation; the other drugs were inactive. The locomotor hyperactivation induced by acute cocaine (10 mg/kg) was enhanced by MSX-3 (5-25 mg/kg) or nafadotride (0.4 mg/kg), while CGS 21680 (0.2 mg/kg), SCH 23390 (0.25 mg/kg), raclopride (0.2-0.8 mg/kg) or 7-OH-PIPAT (0.1 mg/kg) decreased this effect of cocaine. Given during the development of sensitization (in combination with 5-daily cocaine, 10 mg/kg, injections), MSX-3 (5-25 mg/kg) increased, but CGS 21680...Continue Reading

References

Dec 1, 1994·Naunyn-Schmiedeberg's Archives of Pharmacology·M P KungH F Kung
Apr 1, 1994·Cellular and Molecular Neurobiology·N S KulaJ L Neumeyer
Sep 30, 1994·Journal of Medicinal Chemistry·H O KimK A Jacobson
Sep 1, 1993·Brain Research. Brain Research Reviews·T E Robinson, K C Berridge
Sep 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·F BorsiniA Donetti
Dec 1, 1995·Pharmacology, Biochemistry, and Behavior·I UshijimaA Horita
Mar 1, 1996·Pharmacology, Biochemistry, and Behavior·B A MattinglyK Rase
Feb 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P SeemanH H Van Tol
Dec 31, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F J WhiteX T Hu
May 19, 1998·Journal of Psychopharmacology·P W KalivasB A Sorg
Jul 4, 1998·Brain Research. Brain Research Reviews·P GreengardA Nishi
Mar 19, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·K KitaM Takigawa
Jan 1, 1993·Behavioural Pharmacology·J. Stewart, A. Badiani
Apr 28, 2001·Pharmacology, Biochemistry, and Behavior·B A MattinglyM Abel
Jun 9, 2001·Behavioural Pharmacology·E PrzegalinskiJ Siwanowicz
Aug 31, 2001·Pharmacology, Biochemistry, and Behavior·C M KnappC Kornetsky
Jun 14, 2002·Pharmacology, Biochemistry, and Behavior·Charles W Schindler, Gilberto N Carmona
Aug 22, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sergi FerréFrancisco Ciruela
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marzena Karcz-KubichaSergi Ferré
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jiang-Fan ChenMichael A Schwarzschild
May 6, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jenny AhlqvistPeter Salmi

❮ Previous
Next ❯

Citations

Jul 31, 2009·Psychopharmacology·Ryan K Bachtell, David W Self
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Casey E O'NeillRyan K Bachtell
Mar 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Luca FerraroKjell Fuxe
Oct 10, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kjell FuxeLuigi F Agnati
Aug 31, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Valentina ChiodiMaria Rosaria Domenici
Jul 24, 2014·Journal of Caffeine Research·Lauren B Malave, Patricia A Broderick
Feb 10, 2016·Neurotoxicity Research·Javier A MuñizVeronica Bisagno
Sep 13, 2011·Progress in Neurobiology·Geoffrey BurnstockPeter Illes
Mar 24, 2010·Biochemical and Biophysical Research Communications·Daniel MarcellinoKjell Fuxe
Mar 30, 2010·CNS Neuroscience & Therapeutics·K FuxeL F Agnati
Aug 27, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Kaili AnierAnti Kalda
May 15, 2012·Pharmacology, Biochemistry, and Behavior·Susan E DoyleWendy J Lynch
Nov 1, 2015·Neuropharmacology·Ute Krügel
Oct 21, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Casey E O'NeillRyan K Bachtell
Jan 30, 2018·Frontiers in Pharmacology·Inmaculada Ballesteros-YáñezStefania Gessi
Nov 6, 2018·Psychopharmacology·Nicholas S HaynesRyan K Bachtell
Apr 17, 2007·Annals of the New York Academy of Sciences·C Sue CarterDorie Schwertz
Jun 5, 2020·Cells·Karolina WydraMałgorzata Filip
Dec 15, 2006·International Journal of Immunopathology and Pharmacology·E PrzegalińskiM Pokorski
Mar 9, 2017·Frontiers in Cellular Neuroscience·Dasiel O Borroto-EscuelaKjell Fuxe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.